UA128687C2 - Антитіло до gitr - Google Patents

Антитіло до gitr Download PDF

Info

Publication number
UA128687C2
UA128687C2 UAA201811485A UAA201811485A UA128687C2 UA 128687 C2 UA128687 C2 UA 128687C2 UA A201811485 A UAA201811485 A UA A201811485A UA A201811485 A UAA201811485 A UA A201811485A UA 128687 C2 UA128687 C2 UA 128687C2
Authority
UA
Ukraine
Prior art keywords
antibody
antibodies
sitk
tumor
antigen
Prior art date
Application number
UAA201811485A
Other languages
English (en)
Ukrainian (uk)
Inventor
Франк Делфіно
Франк Делфино
Дімітріс Скокос
Димитрис Скокос
Беі Ванг
Беи Ванг
Original Assignee
Редженерон Фармасьютікалс, Інк.
Редженерон Фармасьютикалс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Редженерон Фармасьютікалс, Інк., Редженерон Фармасьютикалс, Инк. filed Critical Редженерон Фармасьютікалс, Інк.
Publication of UA128687C2 publication Critical patent/UA128687C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
UAA201811485A 2016-06-10 2017-06-09 Антитіло до gitr UA128687C2 (uk)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662348353P 2016-06-10 2016-06-10
US201662432023P 2016-12-09 2016-12-09
US201762500312P 2017-05-02 2017-05-02
PCT/US2017/036818 WO2017214548A1 (en) 2016-06-10 2017-06-09 Anti-gitr antibodies and uses thereof

Publications (1)

Publication Number Publication Date
UA128687C2 true UA128687C2 (uk) 2024-10-02

Family

ID=59078260

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201811485A UA128687C2 (uk) 2016-06-10 2017-06-09 Антитіло до gitr

Country Status (19)

Country Link
US (3) US10738126B2 (enExample)
EP (2) EP4344748A3 (enExample)
JP (2) JP7162535B2 (enExample)
KR (1) KR102495601B1 (enExample)
CN (1) CN109563170B (enExample)
AU (1) AU2017278193B9 (enExample)
BR (1) BR112018075434A2 (enExample)
CA (1) CA3027121A1 (enExample)
CL (1) CL2018003515A1 (enExample)
CO (1) CO2018013298A2 (enExample)
IL (1) IL263273B2 (enExample)
MA (1) MA45233A (enExample)
MX (2) MX2018015350A (enExample)
MY (1) MY200162A (enExample)
PH (1) PH12018502502A1 (enExample)
SG (1) SG11201810525XA (enExample)
UA (1) UA128687C2 (enExample)
WO (1) WO2017214548A1 (enExample)
ZA (1) ZA201807920B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
CA3027121A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof
KR20230133934A (ko) 2016-10-11 2023-09-19 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
KR102209364B1 (ko) 2016-12-09 2021-02-01 리제너론 파아마슈티컬스, 인크. T 세포 수용체를 시퀀싱하기 위한 시스템 및 방법 및 이의 용도
CN112020516B (zh) * 2018-03-13 2025-01-03 塔斯克疗法有限公司 用于肿瘤特异性细胞清除的抗-cd25
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP2022519631A (ja) 2019-02-12 2022-03-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 補体および標的抗原に結合する二重特異性抗体を使用するための組成物および方法
RU2734432C1 (ru) 2019-04-23 2020-10-16 Закрытое Акционерное Общество "Биокад" Моноклональное антитело, которое специфически связывается с GITR
EP4085074A4 (en) * 2020-01-02 2024-05-15 Nanjing GenScript Biotech Co., Ltd. ANTI-GITR ANTIBODIES AND THEIR USES
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
MX2022010910A (es) * 2020-03-06 2022-10-07 Regeneron Pharma Anticuerpos anti-gitr y usos de estos.
WO2022148279A1 (zh) * 2021-01-08 2022-07-14 苏州丁孚靶点生物技术有限公司 药物产品及其用途
WO2022150654A2 (en) * 2021-01-08 2022-07-14 10X Genomics, Inc. Antigen-binding polypeptides specific for coronaviruses and uses thereof
JP7671092B2 (ja) * 2021-05-10 2025-05-01 メディマブバイオ インコーポレイテッド 抗ｇｉｔｒ抗体およびその用途
WO2023175614A1 (en) 2022-03-15 2023-09-21 Yeda Research And Development Co. Ltd. Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
CN117003883A (zh) * 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 结合tigit和vegf的双特异性分子及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
DK0920505T3 (da) 1996-08-16 2008-09-08 Schering Corp Pattedyrcelleoverfladeantigener og tilhörende reagenser
US6111090A (en) 1996-08-16 2000-08-29 Schering Corporation Mammalian cell surface antigens; related reagents
US6503184B1 (en) 1997-10-21 2003-01-07 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
US6689607B2 (en) 1997-10-21 2004-02-10 Human Genome Sciences, Inc. Human tumor, necrosis factor receptor-like proteins TR11, TR11SV1 and TR11SV2
WO1999025834A1 (en) 1997-11-18 1999-05-27 Genentech, Inc. Dna19355 polypeptide, a tumor necrosis factor homolog
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
EP1462114A1 (en) 2003-03-28 2004-09-29 Universiteit Utrecht Holding B.V. Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18)
AU2004244626A1 (en) 2003-05-23 2004-12-09 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services GITR ligand and GITR ligand-related molecules and antibodies and uses thereof
US20060099171A1 (en) 2004-11-05 2006-05-11 Masahide Tone Mouse glucocorticoid-induced TNF receptor ligand is costimulatory for T cells
JP5238936B2 (ja) * 2005-03-25 2013-07-17 ジーアイティーアール，インク． Ｇｉｔｒ結合分子およびその使用
WO2007133822A1 (en) 2006-01-19 2007-11-22 Genzyme Corporation Gitr antibodies for the treatment of cancer
US20100061984A1 (en) 2006-01-20 2010-03-11 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
IN2015DN02826A (enExample) 2009-09-03 2015-09-11 Merck Sharp & Dohme
US20130108641A1 (en) 2011-09-14 2013-05-02 Sanofi Anti-gitr antibodies
JP6053688B2 (ja) 2011-10-07 2016-12-27 国立大学法人三重大学 キメラ抗原受容体
KR101566539B1 (ko) 2012-06-08 2015-11-05 국립암센터 신규한 Ｔｈ2 세포 전환용 에피토프 및 이의 용도
AR097306A1 (es) 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
TW201605896A (zh) * 2013-08-30 2016-02-16 安美基股份有限公司 Gitr抗原結合蛋白
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
LT3148579T (lt) 2014-05-28 2021-05-25 Agenus Inc. Anti-gitr antikūnai ir jų panaudojimo būdai
PL3151921T3 (pl) 2014-06-06 2020-02-28 Bristol-Myers Squibb Company Przeciwciała przeciwko receptorowi indukowanego glukokortykoidami czynnika martwicy nowotworu (gitr) i ich zastosowania
RU2017115315A (ru) 2014-10-03 2018-11-08 Дана-Фарбер Кэнсер Инститьют, Инк. Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
EP3212233B1 (en) 2014-10-31 2020-06-24 Oncomed Pharmaceuticals, Inc. Combination therapy for treatment of disease
CA3027121A1 (en) 2016-06-10 2017-12-14 Regeneron Pharmaceuticals, Inc. Anti-gitr antibodies and uses thereof

Also Published As

Publication number Publication date
JP2022159476A (ja) 2022-10-17
PH12018502502A1 (en) 2019-04-08
US20210147565A1 (en) 2021-05-20
EP4344748A2 (en) 2024-04-03
MA45233A (fr) 2019-04-17
WO2017214548A1 (en) 2017-12-14
JP2019521098A (ja) 2019-07-25
US20170355774A1 (en) 2017-12-14
AU2017278193B2 (en) 2024-01-18
CA3027121A1 (en) 2017-12-14
EP4344748A3 (en) 2024-06-12
JP7162535B2 (ja) 2022-10-28
SG11201810525XA (en) 2018-12-28
MY200162A (en) 2023-12-09
EP3468999A1 (en) 2019-04-17
MX2018015350A (es) 2019-08-26
KR20190020297A (ko) 2019-02-28
US10738126B2 (en) 2020-08-11
MX2022014695A (es) 2022-12-16
IL263273A (en) 2018-12-31
EP3468999B1 (en) 2024-01-10
AU2017278193B9 (en) 2024-02-01
AU2017278193A1 (en) 2018-12-13
KR102495601B1 (ko) 2023-02-06
ZA201807920B (en) 2024-01-31
IL263273B1 (en) 2025-06-01
CL2018003515A1 (es) 2019-03-08
US11414494B2 (en) 2022-08-16
CO2018013298A2 (es) 2019-02-19
CN109563170A (zh) 2019-04-02
IL263273B2 (en) 2025-10-01
US20230042324A1 (en) 2023-02-09
NZ748619A (en) 2024-05-31
BR112018075434A2 (pt) 2019-03-19
CN109563170B (zh) 2023-10-13

Similar Documents

Publication Publication Date Title
AU2020200751B2 (en) Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
AU2018250336B2 (en) Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
ES2872077T3 (es) Receptor de antígenos quiméricos anti-variante III del receptor de factor de crecimiento epidérmico y uso de los mismos para el tratamiento de cáncer
JP6560682B2 (ja) 小細胞肺癌に対する標的療法
JP5960597B2 (ja) 癌治療のための併用免疫療法
ES2637416T3 (es) Terapia de combinación que involucra anticuerpos contra claudina 18.2 para el tratamiento del cáncer
JP2021100948A (ja) Ｈｌａ−ａ１−又はｈｌａ−ｃｗ７−拘束性ｍａｇｅを認識するｔ細胞受容体
JP2021045172A (ja) 細胞
ES2902477T3 (es) Péptidos SLC45A2 para inmunoterapia
US11331345B2 (en) PD-1 CAR NK-92 cell and preparation method and use thereof
UA128387C2 (uk) Антитіло до lag3
CN111201038A (zh) Psgl-1拮抗剂及其用途
UA126441C2 (uk) Химерні антигенні рецептори, націлені на bcma, та способи їх застосування
UA125717C2 (uk) Конструкція антитіла до flt3 і cd3
UA118950C2 (uk) Поліпептид, який зв'язує специфічний мембранний антиген простати та комплекс т-клітинного рецептора
UA125382C2 (uk) Антитіла проти людського vista та їх застосування
ES2647568T3 (es) Tratamiento de cáncer
UA125577C2 (uk) Антигензв'язуюча молекула, які містить тримерний ліганд сімейства tnf
UA123428C2 (uk) Спосіб лікування раку, що характеризується раковими клітинами, які експреcують cldn6
BR112021005246A2 (pt) agente terapêutico, e, método de tratamento para câncer
BR112021006182A2 (pt) composições e métodos relativos a células t¿d,d engenheiradas e não engenheiradas para tratamento de tumores hematológicos
ES2665341T3 (es) Anticuerpo anti-DLK-1 humana con actividad antitumoral in vivo
JPWO2016133059A1 (ja) Ｆｓｔｌ１を利用した抗がん剤・転移抑制剤およびその併用剤
CN102348796B (zh) 新型癌抗原eEF2
EP4233882A1 (en) Mitochondria comprising anticancer drug and use thereof